Apparent Diffusion Coefficient as a Predictive Biomarker for Survival in Patients with Treatment-Naive Glioblastoma Using Quantitative Multiparametric Magnetic Resonance Profiling.

[1]  In-Hee Lee,et al.  Quantitative radiomic profiling of glioblastoma represents transcriptomic expression , 2018, Oncotarget.

[2]  Chaofeng Liang,et al.  A Fully-Automatic Multiparametric Radiomics Model: Towards Reproducible and Prognostic Imaging Signature for Prediction of Overall Survival in Glioblastoma Multiforme , 2017, Scientific Reports.

[3]  M. Barış,et al.  Role of mass effect, tumor volume and peritumoral edema volume in the differential diagnosis of primary brain tumor and metastasis , 2016, Clinical Neurology and Neurosurgery.

[4]  Dong Wook Kim,et al.  Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma. , 2016, Radiology.

[5]  T. Dwight,et al.  Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma , 2016, Scientific Reports.

[6]  Paul Kinahan,et al.  Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.

[7]  D. O’Rourke,et al.  Prognostic Value of Dynamic Susceptibility Contrast-Enhanced and Diffusion-Weighted MR Imaging in Patients with Glioblastomas , 2015, American Journal of Neuroradiology.

[8]  W. Pope.  Genomics of brain tumor imaging. , 2015, Neuroimaging clinics of North America.

[9]  Susan M. Chang,et al.  Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab , 2014, Journal of Neuro-Oncology.

[10]  Maciej A. Mazurowski,et al.  Computer-extracted MR imaging features are associated with survival in glioblastoma patients , 2014, Journal of Neuro-Oncology.

[11]  H. Fathallah-Shaykh,et al.  Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters , 2014, Journal of Neuro-Oncology.

[12]  G. Reifenberger,et al.  MGMT testing—the challenges for biomarker-based glioma treatment , 2014, Nature Reviews Neurology.

[13]  Luke Macyszyn,et al.  Pattern analysis of dynamic susceptibility contrast-enhanced MR imaging demonstrates peritumoral tissue heterogeneity. , 2014, Radiology.

[14]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[15]  A. Lagares,et al.  A Prognostic Model Based on Preoperative MRI Predicts Overall Survival in Patients with Diffuse Gliomas , 2014, American Journal of Neuroradiology.

[16]  Christopher P. Hess,et al.  Susceptibility-weighted MR imaging of radiation therapy-induced cerebral microbleeds in patients with glioma: a comparison between 3T and 7T , 2014, Neuroradiology.

[17]  R. Gillies,et al.  Quantitative imaging in cancer evolution and ecology. , 2013, Radiology.

[18]  Jordan M. Malof,et al.  Imaging descriptors improve the predictive power of survival models for glioblastoma patients. , 2013, Neuro-oncology.

[19]  G. Reifenberger,et al.  Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations , 2013, Clinical Cancer Research.

[20]  William D. Dunn,et al.  MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. , 2013, Radiology.

[21]  D. Yousem,et al.  ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor?--a meta-analysis. , 2013, AJR. American journal of roentgenology.

[22]  A. Bozzao,et al.  Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status , 2013, European Radiology.

[23]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[24]  Andre Dekker,et al.  Radiomics: the process and the challenges. , 2012, Magnetic resonance imaging.

[25]  Christos Davatzikos,et al.  GLISTR: Glioma Image Segmentation and Registration , 2012, IEEE Transactions on Medical Imaging.

[26]  T. Cloughesy,et al.  Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma , 2012, American Journal of Neuroradiology.

[27]  M S Brown,et al.  Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma , 2011, American Journal of Neuroradiology.

[28]  T. Mikkelsen,et al.  Predicting survival in glioblastomas using diffusion tensor imaging metrics , 2010, Journal of magnetic resonance imaging : JMRI.

[29]  S. Leenstra,et al.  Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide , 2010, British Journal of Cancer.

[30]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[31]  T. Hirai,et al.  Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. , 2007, Radiology.

[32]  Toshihiro Kumabe,et al.  Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. , 2006, Radiology.

[33]  Daniel P Barboriak,et al.  Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. , 2006, Radiology.

[34]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[35]  J. Herman,et al.  Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer , 2004, Oncogene.

[36]  R. Bammer.  Basic principles of diffusion-weighted imaging. , 2003, European journal of radiology.

[37]  Usha Sinha,et al.  Relationships Between Choline Magnetic Resonance Spectroscopy, Apparent Diffusion Coefficient and Quantitative Histopathology in Human Glioma , 2000, Journal of Neuro-Oncology.

[38]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[39]  Toshinori Hirai,et al.  Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.

[40]  S. Plevritis,et al.  Glioblastoma Multiforme: Exploratory Radiogenomic Analysis by Using Quantitative Image Features. , 2015, Radiology.

[41]  Jill S. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 , 2015, Neuro-oncology.

[42]  Benjamin M. Ellingson,et al.  Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics , 2014, Current Neurology and Neuroscience Reports.

[43]  G. Reifenberger,et al.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.